For the SYUCC patient cohort, we retrospectively examined 64 patients with R/M NPC who were treated with anti-PD-(L)1 or anti-CTLA-4 (NCT02721589 and NCT02593786) as well as 73 patients with NSCLC who underwent anti-PD-(L)1 monotherapy. The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.